Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Benefits of Continued Use of Ovarian Function Suppression After 5 Years
Sponsor: Hongmei Zheng, PhD
Summary
To observe and evaluate the clinical efficacy and safety of continuous use of OFS for premenopausal patients with early breast cancer after 5 years use of OFS. This study is a multicenter, prospective, observational, non randomized controlled, open-label real world study based on hospital medical record system data, aimed at evaluating the benefits of continuing to use OFS after 5 years of use. The retrospective analysis plan includes patient data from September 1, 2023 to September 1, 2026. Join two cohorts: the continued use group and the discontinued use group after 5 years of OFS, respectively.
Official title: A Multicenter, Open-label, Non-randomized Controlled Real World Study Comparing the Benefits of Continued Use of Ovarian Function Suppression After 5 Years
Key Details
Gender
FEMALE
Age Range
18 Years - 60 Years
Study Type
OBSERVATIONAL
Enrollment
1200
Start Date
2023-09-01
Completion Date
2028-09-01
Last Updated
2025-03-17
Healthy Volunteers
No
Conditions
Interventions
OFS continues to use group after 5 years use
Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
Immunohistochemical detection of HR status
Enrolled patients must be HR-positive premenopausal breast cancer patients
Locations (1)
Wu Xinhong
Wuhan, Hubei, China